Diuretic use, progressive heart failure, and death in patients in the DIG study

被引:73
作者
Domanski, M [1 ]
Tian, X
Haigney, M
Pitt, B
机构
[1] NHLBI, Clin Trials Grp, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA
[2] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA
[3] Uniformed Serv Med Sch, Div Cardiol, Bethesda, MD USA
[4] Univ Michigan, Sch Med, Div Cardiol, Ann Arbor, MI 48109 USA
关键词
heart failure; diuretics; sudden cardiac death; SOLVD study;
D O I
10.1016/j.cardfail.2006.03.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nonpotassium-sparing diuretics (NPSDs), have been associated with increased sudden cardiac death (SCD) and progressive heart failure (HF) death in HF patients. Methods and Results: In 6797 Digitalis Investigation Group study patients, risk ratios were calculated for death, cardiovascular death (CVD), death from worsening HF, SCD, and HF hospitalization among those taking a potassium-sparing (PSD), NPSD, or no diuretic. Compared with not taking diuretic, risk of death (relative risk [RR] 1.36, 95% confidence interval [CI] 1.17-1.59, P < .0001), CVD (RR = 1.38, 95% CI 1.17-1.63, P = .0001), progressive HF death (RR = 1.41, 95% CI 1.06-1.89, P = .02), SCD (RR = 1.67, 95% CI 1.23-2.27, P = .001), and HF hospitalization (RR = 1.68, 95% CI 1.41-1.99, P < .0001) were increased with NPSD. There was no significant difference in any end point for patients taking only PSD compared to no diuretic. PSD only subjects were less likely than NPSD subjects to be hospitalized for HF (RR = 0.71, 95% CI 0.52-0.96, P = .02). Conclusion: NPSDs are associated with increased risk of death, CVD, progressive HF death, SCD, and HF hospitalization. A randomized trial is needed to assess the role of NPSDs versus PSDs in HF patients.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 15 条
  • [1] Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
  • [2] BAYLISS J, 1987, BRIT HEART J, V57, P17
  • [3] BENEDICT GR, 1993, J AM COLL CARDIOL S, V22, pA146
  • [4] Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
    Cooper, HA
    Dries, DL
    Davis, CE
    Shen, YL
    Domanski, MJ
    [J]. CIRCULATION, 1999, 100 (12) : 1311 - 1315
  • [5] *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P523
  • [6] Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD)
    Domanski, M
    Norman, J
    Pitt, B
    Haigney, M
    Hanlon, S
    Peyster, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (04) : 705 - 708
  • [7] ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
    Hunt, SA
    Baker, DW
    Chin, MH
    Cinquegrani, MP
    Feldman, AM
    Francis, GS
    Ganiats, TG
    Goldstein, S
    Gregoratos, G
    Jessup, ML
    Noble, RJ
    Packer, M
    Silver, MA
    Stevenson, LW
    Gibbons, RJ
    Antman, EM
    Alpert, JS
    Faxon, DP
    Fuster, V
    Gregoratos, G
    Jacobs, AK
    Hiratzka, LF
    Russell, RO
    Smith, SC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (07) : 2101 - 2113
  • [8] Hypovolemia and neurovascular control during orthostatic stress
    Kimmerly, DS
    Shoemaker, JK
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (02): : H645 - H655
  • [9] K+ depletion and the progression of hypertensive disease or heart failure -: The pathogenic role of diuretic-induced aldosterone secretion
    Laragh, JH
    Sealey, JE
    [J]. HYPERTENSION, 2001, 37 (02) : 806 - 810
  • [10] Furosemide and the progression of left ventricular dysfunction in experimental heart failure
    McCurley, JM
    Hanlon, SU
    Wei, SK
    Wedam, EF
    Michalski, M
    Haigney, MC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (06) : 1301 - 1307